Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials: JACC Review Topic of the Week.

Gregson J, Sharples L, Stone GW, Burman CF, Öhrn F, Pocock S.

J Am Coll Cardiol. 2019 Oct 22;74(16):2102-2112. doi: 10.1016/j.jacc.2019.08.1034. Review.

PMID:
31623769
2.

Modestly weighted logrank tests.

Magirr D, Burman CF.

Stat Med. 2019 Sep 10;38(20):3782-3790. doi: 10.1002/sim.8186. Epub 2019 May 26.

PMID:
31131462
3.

Lessons learned from IDeAl - 33 recommendations from the IDeAl-net about design and analysis of small population clinical trials.

Hilgers RD, Bogdan M, Burman CF, Dette H, Karlsson M, König F, Male C, Mentré F, Molenberghs G, Senn S.

Orphanet J Rare Dis. 2018 May 11;13(1):77. doi: 10.1186/s13023-018-0820-8. Review.

4.

Optimized adaptive enrichment designs.

Ondra T, Jobjörnsson S, Beckman RA, Burman CF, König F, Stallard N, Posch M.

Stat Methods Med Res. 2019 Jul;28(7):2096-2111. doi: 10.1177/0962280217747312. Epub 2017 Dec 18.

5.

A decision theoretical modeling for Phase III investments and drug licensing.

Miller F, Burman CF.

J Biopharm Stat. 2018;28(4):698-721. doi: 10.1080/10543406.2017.1377729. Epub 2017 Oct 20.

PMID:
28920757
6.

Late-stage pharmaceutical R&D and pricing policies under two-stage regulation.

Jobjörnsson S, Forster M, Pertile P, Burman CF.

J Health Econ. 2016 Dec;50:298-311. doi: 10.1016/j.jhealeco.2016.06.002. Epub 2016 Oct 5.

PMID:
27776744
7.

Optimizing Trial Designs for Targeted Therapies.

Ondra T, Jobjörnsson S, Beckman RA, Burman CF, König F, Stallard N, Posch M.

PLoS One. 2016 Sep 29;11(9):e0163726. doi: 10.1371/journal.pone.0163726. eCollection 2016.

8.

A decision theoretic approach to optimization of multiple testing procedures.

Lisovskaja V, Burman CF.

Biom J. 2015 Jan;57(1):64-75. doi: 10.1002/bimj.201300186. Epub 2014 Nov 13.

PMID:
25394261
9.

Optimizing Drug Development Programs: Type 2 Diabetes Case Study.

Antonijevic Z, Kimber M, Manner D, Burman CF, Pinheiro J, Bergenheim K.

Ther Innov Regul Sci. 2013 May;47(3):363-374. doi: 10.1177/2168479013480501.

PMID:
30231431
10.

On the choice of doses for phase III clinical trials.

Lisovskaja V, Burman CF.

Stat Med. 2013 May 10;32(10):1661-76. doi: 10.1002/sim.5632. Epub 2012 Sep 30.

PMID:
23023767
11.

Modelling and simulation in the pharmaceutical industry--some reflections.

Burman CF, Wiklund SJ.

Pharm Stat. 2011 Nov-Dec;10(6):508-16. doi: 10.1002/pst.523. Epub 2011 Dec 8.

PMID:
22162317
12.

The dual test: safeguarding p-value combination tests for adaptive designs.

Burman CF, Lisovskaja V.

Stat Med. 2010 Mar 30;29(7-8):797-807. doi: 10.1002/sim.3704.

PMID:
20213723
13.

A recycling framework for the construction of Bonferroni-based multiple tests.

Burman CF, Sonesson C, Guilbaud O.

Stat Med. 2009 Feb 28;28(5):739-61. doi: 10.1002/sim.3513.

PMID:
19142850
14.

Discussion of the paper "Adaptive dose-ranging designs".

Burman CF.

J Biopharm Stat. 2007;17(6):1005-11; discussion 1029-32. No abstract available.

PMID:
18027210
15.

Adaptive designs in clinical drug development: opportunities, challenges, and scope reflections following PhRMA's November 2006 workshop.

Krams M, Burman CF, Dragalin V, Gaydos B, Grieve AP, Pinheiro J, Maurer W, Gallo P.

J Biopharm Stat. 2007;17(6):957-64. Erratum in: J Biopharm Stat. 2008;18(2):403. Gallo, Paul [added].

PMID:
18027207
16.

Are flexible designs sound?

Burman CF, Sonesson C.

Biometrics. 2006 Sep;62(3):664-9; discussion 670-83.

PMID:
16984302
17.

Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease -- results from a randomized trial programme.

Malfertheiner P, Dent J, Zeijlon L, Sipponen P, Veldhuyzen Van Zanten SJ, Burman CF, Lind T, Wrangstadh M, BayerdOrffer E, Lonovics J.

Aliment Pharmacol Ther. 2002 Aug;16(8):1431-42.

18.

The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection.

Bardhan K, Bayerdörffer E, Veldhuyzen Van Zanten SJ, Lind T, Mégraud F, Delchier JC, Hellblom M, Stubberöd A, Burman CF, Gromark P, Zeijlon L.

Helicobacter. 2000 Dec;5(4):196-201.

PMID:
11179983
19.

Efficacy of two different dosage regimens of omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infection.

Bayerdörffer E, Lonovics J, Dité P, Díete U, Domján L, Kisfalvi I, Mégraud F, Pap A, Sipponen P, Burman CF, Zeijlon L.

Aliment Pharmacol Ther. 1999 Dec;13(12):1639-45.

20.

Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study.

Mégraud F, Lehn N, Lind T, Bayerdörffer E, O'Morain C, Spiller R, Unge P, van Zanten SV, Wrangstadh M, Burman CF.

Antimicrob Agents Chemother. 1999 Nov;43(11):2747-52.

Supplemental Content

Loading ...
Support Center